Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070223 · ClinicalTrials.gov registry record · Phase 3
PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)
A Phase 3 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 3
- Development phase
- 602
- Enrollment target
NCT03070223 is a Phase 3 study that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 602 participants.
The verdict
NCT03070223, a Phase 3 study, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 602 participants
- Enrollment target
Study Summary
Aging with HIV is associated with earlier development of frailty (weakness) or disability, including loss of physical and muscle strength, and walking speed. Few treatments have been shown to prevent or slow these impairments in people with or without HIV. Some studies have suggested that the class of drugs called statins (for example, pitavastatin) might be helpful in slowing frailty or disability. This might happen by decreasing fat within the muscle or by decreasing inflammation markers (substances in the blood that determine how the body reacts to infection or irritation) in the blood. Other studies have shown that statins increase the risk of muscle aches and pains. This ancillary study was done to determine the impact of the drug pitavastatin on physical and muscle function.
Interventions
- DRUG Placebos
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2023-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070223
The ClinicalTrials.gov registry entry for NCT03070223 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03070223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03070223 about?
NCT03070223 is a clinical study titled "PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)". Aging with HIV is associated with earlier development of frailty (weakness) or disability, including loss of physical and muscle strength, and walking speed. Few treatments have been shown to prevent or slow these impairments in people with or without HIV. Some studies have suggested that the class ...
What is the current status of trial NCT03070223?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2017-03-14. Estimated completion is 2023-08-21.
What interventions are being tested in trial NCT03070223?
The interventions under investigation include: Placebos (DRUG), Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT03070223?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.